How much platinum-based chemotherapy is enough in NSCLC?

被引：0
|
作者：
Solange Peters
Alex A. Adjei
机构：
[1] Centre Hospitalier Universitaire Vaudois (CHUV),Oncology Department
[2] Roswell Park Cancer Institute,undefined
来源：
Nature Reviews Clinical Oncology | 2015年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced non-small-cell lung cancer has long been unclear. Most guidelines recommend a maximum of 4–6 cycles. Rossi and colleagues now suggest that four chemotherapy cycles is the optimal regimen.
引用
收藏
页码：8 / 10
页数：2
相关论文
共 50 条
  • [21] Peripheral neurotoxicity of platinum-based chemotherapy
    Cavaletti, Guido
    NATURE REVIEWS CANCER, 2008, 8 (01) : 72 - 72
  • [22] Peripheral neurotoxicity of platinum-based chemotherapy
    Guido Cavaletti
    Nature Reviews Cancer, 2008, 8 : 72 - 72
  • [23] The resurgence of platinum-based cancer chemotherapy
    Lloyd Kelland
    Nature Reviews Cancer, 2007, 7 : 573 - 584
  • [24] Establishing a Prediction Model for the Efficacy of Platinum-Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study
    Xiao, Qi
    Mao, Chenxue
    Gao, Ying
    Huang, Hanxue
    Yu, Bing
    Yu, Lulu
    Li, Xi
    Mao, Xiaoyuan
    Zhang, Wei
    Yin, Jiye
    Liu, Zhaoqian
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [25] NGS based profiling of homologous recombination genes to predict response to platinum-based chemotherapy in NSCLC.
    Zhang, Linlin
    Wang, Xin
    Song, Hui
    Meng, Fanlu
    Yu, Guowei
    Zhong, Diansheng
    CANCER RESEARCH, 2021, 81 (13)
  • [26] IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients
    Nishio, Makoto
    Saito, Haruhiro
    Goto, Koichi
    Watanabe, Satoshi
    Sueoka-Aragane, Naoko
    Okuma, Yusuke
    Kasahara, Kazuo
    Chikamori, Kenichi
    Nakagawa, Yuki
    Kawakami, Tomohisa
    CANCER SCIENCE, 2021, 112 (04) : 1534 - 1544
  • [27] Association of BAFFR expression in CAFs with overall survival and response to platinum-based chemotherapy in NSCLC.
    Dimtrakopoulos, Fotinos-Ioannis D.
    Kottorou, Anastasia E.
    Antonacopoulou, Anna G.
    Nikolakopoulos, Achilleas
    Panagopoulos, Nikolaos
    Kalofonou, Melpomeni
    Dougenis, Dimitrios
    Koutras, Angelos
    Makatsoris, Thomas
    Tzelepi, Vasiliki
    Kalofonos, Haralabos
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy
    Kaltsas, Konstantinos
    Anevlavis, Stavros
    Pataka, Athanasia
    Kouliatsis, Georgios
    Pozova, Sofia
    Bouros, Demosthenes
    Froudarakis, Marios
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [29] Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
    Marmarelis, M. E.
    Lee, S. -H.
    Spira, A. I.
    Ou, S. -H. I.
    Waqar, S.
    Li, S.
    Thayu, M.
    Knoblauch, R. E.
    Bauml, J. M.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S68 - S68
  • [30] Platinum-based chemotherapy combined with endostar in the treatment of advanced NSCLC: A real world study.
    Jiang, Wei
    Sun, Wei
    Li, Wenhui
    Gao, Jing
    Wang, Hui
    Zhou, Wei
    Liang, Jing
    Aa, Lixiang
    Zhao, Changhong
    Wang, Luhua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345